antagonisten - FACEIT level 10, 2,719 ELO

Sweden
On FACEIT since 2016 190 matches tracked 75 matches in 30 days
Last updated:

antagonisten at a glance

Level 10 2,719 ELO best map Anubis (61%)
2,500-2,749 ELO

Last 20 matches compared with 2,994 players in this group: K/R, ADR and win rate above average.

RatingCalculated with the HLTV Rating 1.0 formula from kills, deaths and multi-kills per round. 1.00 is an average match.
better than 75%
1.13
SpreadHow much the rating swings from match to match. The smaller, the more consistent. ±0.37 ConsistencyShare of matches with a rating of 0.90 or higher. 80%
K/R
0.83
better than 82% of players
2,500-2,749 ELO avg: 0.75
Last 12 months
ADR
90.8
better than 86% of players
2,500-2,749 ELO avg: 81.1
Last 12 months
Win rate
60%
better than 74% of players
2,500-2,749 ELO avg: 50%
Last 12 months

Facts

26 ELO Next goal That is about 2 wins in a row.
4 W · 2 L Best day +63 ELO · Oct 7, 2026
4 Comebacks last 90 days
Inferno Favorite map 51 of 190 matches
Anubis 61% Map pool tip weakest: Mirage 44%
5 knife kills Rare kills last 90 days
On Wednesdays Best time 64% win rate vs. 54%
FormMapsTiming

26 ELO away from the recorded peak (2,745). That is about 2 wins in a row. 4:2 on Oct 7, 2026 (+63 ELO, last 90 days). 4 wins after trailing at halftime (last 90 days). Most played: Inferno (51 of 190 matches). Strongest map: Anubis (61% win rate, 31 matches). Weakest: Mirage (44%, 45 matches). 5 knife kills (last 90 days). Best results on Wednesdays: 64% win rate vs. 54% overall (36 matches).

About antagonisten

antagonisten plays CS2 on FACEIT level 10 with 2,719 ELO. The stats cover 190 matches. The strongest map is Anubis with a 61% win rate in 31 matches. Most played: Inferno with 51 matches and a 59% win rate. Biggest strength: Utility hit rate at 51%, better than 99% of level 10 · 2,500-2,749 ELO players. antagonisten won 4 matches after trailing at halftime (last 90 days). Last 20 matches: 12 wins, 8 losses, -50 ELO. antagonisten does best on Wednesdays: 64% win rate in 36 matches.